Tag Archives: Kedrion Biopharma

November, 2016

  • 7 November

    FDA Accepts Kedrion and Kamada’s BLA for Human Rabies Immunoglobulin

    FORT LEE, N.J. & NESS ZIONA, Israel–(BUSINESS WIRE)–Kedrion Biopharma, and Kamada Ltd. (NASDAQ and TASE:KMDA), two leading human-derived protein therapeutics companies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a human anti-rabies immunoglobulin (IgG) therapy. Rabies is a …

March, 2016

January, 2016